DEF 14A: Harvard Apparatus Regenerative Technology Announces Annual Stockholders Meeting

Harvard Apparatus Regenerative Technology, Inc. will hold its annual meeting of stockholders on June 20, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.

Summary

• Harvard Apparatus Regenerative Technology, Inc. (HART) is holding its Annual Meeting of Stockholders on June 20, 2024.
• The meeting will take place at the company's principal executive offices in Holliston, MA.
• Stockholders will vote on the election of three Class II Directors for a three-year term expiring in 2027.
• They will also vote to ratify the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• Additionally, stockholders will cast a non-binding advisory vote on the compensation of the company's named executive officers.
• The Board of Directors recommends voting FOR the election of the director nominees, FOR the ratification of Marcum LLP, and FOR the non-binding approval of executive compensation.
• The record date for determining stockholders eligible to vote at the meeting was April 22, 2024.
• As of the record date, there were 14,315,091 shares of Common Stock outstanding and entitled to vote.
• The company is using the internet as its primary means of furnishing proxy materials to shareholders.
• The proxy statement and annual report are available at www.edocumentview.com/HRGN.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The Board's recommendations to vote FOR all proposals suggest a positive outlook from management's perspective.

Positives

• The Board of Directors is actively engaged in corporate governance, with established Audit, Compensation, and Governance Committees.
• The company provides multiple avenues for stockholders to access proxy materials and vote, including online, telephone, and mail.
• The Board of Directors recommends voting FOR all proposals, indicating confidence in the company's direction and management.
• The company is committed to transparency, providing detailed information on director and executive compensation.
• The Audit Committee has pre-approved all audit and non-audit services performed by the independent registered public accounting firm.

Negatives

• The company is a smaller reporting company and has elected to comply with reduced disclosure requirements.
• The Compensation Committee did not hold a formal meeting in 2023, but acted by written consent.
• Harvard Bioscience owns 4.9% of the company, which is just under the 5% threshold for disclosure as a greater than 5% holder.

Risks

• Failure to ratify the appointment of Marcum LLP as the independent registered public accounting firm could necessitate a change in auditors.
• The advisory vote on executive compensation, while non-binding, could influence future compensation decisions if a significant number of stockholders vote against the proposal.
• The company's reliance on a few key executives could pose a risk if any of them were to leave or become incapacitated.
• The company's success depends on its ability to attract and retain qualified directors and executive officers.
• The company's insider trading policy prohibits hedging, which could limit the ability of directors, officers, and employees to manage their risk exposure.

Future Outlook

The document outlines the matters to be voted on at the upcoming Annual Meeting and provides guidance on how stockholders can participate in the process.

Management Comments

• Junli (Jerry) He, Chief Executive Officer, Director, and Chairman, invites stockholders to attend the Annual Meeting and encourages them to vote.
• The Board of Directors recommends voting FOR the election of director nominees, FOR the ratification of Marcum LLP, and FOR the non-binding approval of executive compensation.

Industry Context

As a smaller reporting company, Harvard Apparatus Regenerative Technology operates within the broader biotechnology and regenerative medicine industry, facing competition and regulatory considerations common to the sector.

Comparison to Industry Standards

• The company's executive compensation practices are disclosed in accordance with SEC regulations for smaller reporting companies.
• The company's corporate governance structure, including the establishment of Audit, Compensation, and Governance Committees, aligns with standard practices for publicly traded companies.
• The company's engagement of an independent registered public accounting firm and its adherence to audit committee independence requirements are consistent with industry norms.
• The company's proxy statement provides detailed information on director and executive compensation, security ownership, and related party transactions, as required by SEC regulations.

Management Changes

Related Party Transactions

• On February 1, 2024, the Company entered into a loan arrangement with Junli He, the Chairman and Chief Executive Officer of the Company (the Lender), pursuant to which the Lender has agreed to loan the Company an aggregate amount of $500,000 as evidenced by a Bridge Note executed by the Company in favor of, and accepted by, the Lender (the Bridge Note).

Stakeholder Impact

• Stockholders have the opportunity to influence the company's direction through their votes on director elections, auditor ratification, and executive compensation.
• Employees are affected by the company's executive compensation policies and benefit plans.
• The company's performance and governance practices impact its reputation and relationships with customers, suppliers, and creditors.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The Annual Meeting will be held on June 20, 2024, where the results of the voting will be announced.
• The Board of Directors will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.
• The company will continue to engage with stockholders and provide updates on its business and financial performance.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, executive compensation, Marcum LLP, corporate governance, voting, Harvard Apparatus Regenerative Technology